Navigation Links
Wellspring Biosciences Founder Publishes In Nature On Discovery of Small Molecule Inhibitors of K-Ras
Date:11/20/2013

LA JOLLA, Calif., Nov. 20, 2013 /PRNewswire/ -- Wellspring Biosciences, a leading biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of cancer, announced today a publication from Kevan Shokat, Ph.D., one of its founders and chairman of its scientific advisory board, in the journal Nature that describes the discovery of small molecules that bind irreversibly to a common oncogenic mutant, K-Ras G12C.

Ras genes are mutated in up to 30% of human cancers and are among the most important therapeutic targets in the treatment of human cancer.  Yet, to date, not a single drug that targets Ras proteins or acts on Ras-driven cancers has been developed successfully.  Indeed, tumors harboring Ras mutations are among the most difficult to treat and are excluded from treatment with many therapies.

Dr. Shokat serves as Professor and Chair in the Department of Cellular and Molecular Pharmacology at UCSF as well as Investigator, Howard Hughes Medical Institute.  "We are extremely excited to find a druggable binding pocket on K-Ras, the most frequently mutated oncogene in human cancer" said Professor Shokat.  "Our findings can serve as the starting point for drug-discovery efforts targeting the G12C form of K-Ras and eventually other cancer causing alleles of K-Ras."

"The proto-oncogene K-Ras is mutated in a wide array of human cancers, most of which are aggressive and respond poorly to standard therapies," said Yi Liu, Ph.D., Chief Scientific Officer of Wellspring Biosciences.  "This represents one of the most promising approaches to target K-Ras yet reported, and we look forward to continuing to advance this exciting science in the potentially transformative area of drug development."

In February 2013, Wellspring Biosciences, through its affiliate Araxes Pharma, entered into an exclusive arrangement with Janssen Biotech, Inc. to develop first-in-class therapeutics against G12C K-Ras for the treatment of cancer.  Under the agreement, Araxes Pharma will advance the program through Phase I to clinical proof-of-concept.  Thereafter, Janssen has an option for the continued development and worldwide commercialization of products arising under the agreement.

The paper, titled "Inhibitors of K-Ras G12C allosterically control GTP affinity and effector interactions" was made available on November 20, 2013 in the advanced online publication of Nature at http://dx.doi.org/10.1038/nature12796.

About Wellspring Biosciences

Wellspring Biosciences LLC is a privately held, drug discovery and development company committed to creating breakthrough medicines for the treatment of cancer and other serious diseases.  Our team has a proven track record, having previously played pivotal roles in the discovery of clinical-stage compounds for the treatment of cancer and immune-mediated inflammatory diseases at Intellikine.  Araxes Pharma LLC, an affiliate of Wellspring Biosciences, is engaged in an exclusive arrangement with Janssen Biotech, Inc.  Wellspring Biosciences is located in La Jolla, California.  For more information, please visit the company's website at www.wellspringbiosciences.com.

Contact: Anna Nadolski, 858-500-8803, anna@wellspringbiosciences.com


'/>"/>
SOURCE Wellspring Biosciences LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Springer will publish lecture series with the Mathematical Biosciences Institute
2. Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation
3. Inflection Biosciences licenses preclinical oncology programs from the CNIO
4. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
5. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
6. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
7. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
8. Alfred Russel Wallace: Co-founder of the theory of biological evolution
9. Google, Intel founders support undersea research by UMass Amherst microbiologist
10. Dr. Anurag Agrawal to give Founders Memorial lecture at Entomology 2013
11. Biophysical Society names 2013 Distinguished Service, Emily M. Gray, and Founders awardees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2016)... Securus Technologies, a leading provider of civil and criminal ... monitoring, announced today that it has offered a challenge ... technology judge determine who has the largest and best ... platform, and the best customer service. "ICSolutions ... we do – which clearly is not the case ...
(Date:11/17/2016)... that it has just released a new white paper authored by Zettar that covers ... data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a complicated ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
Breaking Biology News(10 mins):
(Date:12/4/2016)... CAMBRIDGE, Mass. and ... 2016 SystemOne, a company focused on ... for the developing world, and Daktari Diagnostics, a ... with its portable and ultrasensitive immunoassay-based CarePlatform™, today ... and license agreement to integrate Daktari,s technology platform ...
(Date:12/2/2016)... 2, 2016 CytRx Corporation (NASDAQ: ... in oncology, today announced the appointment of Earl ... consultant, and private healthcare investor, to its Board of ... with clinical and strategic experience at the highest level," ... CEO. "As one of the world,s leading orthopedic surgeons, ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... (CSS) and the popularity of US Single Day Events (SDE) to organize a ... Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and life sciences industry ...
(Date:12/2/2016)... ... December 02, 2016 , ... Robots will storm the Prudential Center in Boston, ... The event, which is held on the United Nations International Day of Persons with ... into the workplace. Suitable Technologies is partnering with NTI to showcase how technology can ...
Breaking Biology Technology: